Skip to main content
. 2004 Oct 15;10(20):2984–2988. doi: 10.3748/wjg.v10.i20.2984

Table 3.

Serum amino acid levels in 25 cases before and after the first ALSS therapy (mean ± SE)

Pre-therapy (μmol/L) After therapy (μmol/L)
Cys 65.63 ± 41.40 53.74 ± 26.86a
Phe 94.78 ± 62.00 80.92 ± 40.75a
Ala 256.51 ± 123.73 267.84 ± 138.32
Gly 194.89 ± 83.43 212.50 ± 106.07
Glu 118.50 ± 89.65 116.85 ± 91.26
Gln 494.16 ± 218.91 515.84 ± 208.81
Met 185.85 ± 142.33 149.91 ± 134.16b
Arg 170.44 ± 231.69 143.18 ± 175.92a
Lys 220.72 ± 168.05 190.29 ± 136.28
Tyr 121.98 ± 82.82 104.44 ± 59.94a
Leu 73.73 ± 58.81 78.17 ± 43.74
Orn 113.99 ± 94.58 92.84 ± 52.93
Tau 46.41 ± 27.34 43.51 ± 32.90
Ser 123.78 ± 64.83 122.22 ± 61.29
Thr 165.60 ± 83.34 152.94 ± 83.42
Asp 16.22 ± 10.72 13.38 ± 7.87
Asn 59.40 ± 46.09 64.52 ± 49.46
Val 121.69 ± 75.01 126.35 ± 68.72
Ile 44.86 ± 36.61 46.29 ± 25.88
His 96.18 ± 73.85 87.86 ± 51.56
BCAA/AAA 1.18 ± 0.39 1.52 ± 0.77a
a

P < 0.05;

b

P < 0.001 vs pre-therapy group.